Short Interest in MYOS Co. (NASDAQ:MYOS) Drops By 33.6%

MYOS Co. (NASDAQ:MYOS) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totalling 101,700 shares, a decrease of 33.6% from the June 30th total of 153,200 shares. Based on an average trading volume of 34,600 shares, the days-to-cover ratio is presently 2.9 days. Currently, 2.4% of the company’s stock are short sold.

Separately, ValuEngine cut MYOS from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th.

Shares of MYOS stock remained flat at $$1.60 during trading hours on Tuesday. The stock had a trading volume of 4,864 shares, compared to its average volume of 40,591. The company has a market cap of $14.67 million, a price-to-earnings ratio of -3.56 and a beta of 0.78. The business’s 50-day simple moving average is $1.61. MYOS has a fifty-two week low of $1.04 and a fifty-two week high of $2.02. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.21 and a current ratio of 2.74.

MYOS (NASDAQ:MYOS) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $0.14 million. MYOS had a negative net margin of 603.47% and a negative return on equity of 93.90%. As a group, equities research analysts forecast that MYOS will post -0.5 earnings per share for the current fiscal year.

An institutional investor recently raised its position in MYOS stock. Community Capital Management Inc. grew its position in MYOS Co. (NASDAQ:MYOS) by 295.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 142,452 shares of the company’s stock after purchasing an additional 106,392 shares during the period. Community Capital Management Inc. owned about 1.55% of MYOS worth $217,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 5.13% of the company’s stock.

MYOS Company Profile

MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

Featured Article: Investing in Growth Stocks

Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with MarketBeat.com's FREE daily email newsletter.